The prevalence of the components of metabolic syndrome in the studied population is significantly higher, and both the overall prevalence of metabolic syndrome and its individual components increase with age. The most pronounced rise in metabolic syndrome and its components is observed after the age of 40, while the distribution dynamics of individual components remain unclear. In addition to cholesterol and beta-lipoprotein levels, a correlation is observed between body mass parameters and the investigated risk factors.

Arterial hypertension, obesity, hyperlipidemia, diabetes mellitus.

Abdukhakimova N.A. Features of the clinical course of gout in metabolic syndrome. diss. Tashkent, 2011. P. 152.

Akbarova M., Mamasoliev N.S. Epidemiological, clinical, biorhythmological and preventive aspects of chronic heart failure in the conditions of the sharply continental climate of the Fergana Valley/V-Congress of Cardiologists of the CIS countries in the journal Cardiology of the CIS. 2005, vol.-3, No 2, art. 17.

Tursunov Kh.Kh., Babich S.M. Features of the Coronary Heart Disease Flow in the Conditions of the Sharply Continental Climate of the Fergana Valley of Uzbekistan. – 2008. – No 3 – P. 31-34

Kamilova U.K., Rasulova Z.D. Study of the comparative efficacy of losartan and lisinopril on glomerulo-tubular markers of renal dysfunction in patients with chronic heart failure. Cardiovascular therapy and prevention. 2015; 14(2):41-45. https://doi.org/10.15829/1728-8800-2015-2-41-45

Shagazatova B.Kh., Assessment of the quality of outpatient and polyclinic observation of patients with diabetes mellitus // Vrachebnoye delo, 2013.

American Diabetes Association. Prevention or delay of type 2 diabetes. Diabetes Care. 2017;40 (Suppl 1): S44–S47.

Aspry KE, Van Horn L, Carson JAS, et al.: Medical Nutrition Education, Training, and Competencies to Advance Guideline-Based Diet Counseling by Physicians: A Science Advisory from the American Heart Association. Circulation. 2018;137(23): e821–e841. 10.1161/CIR.0000000000000563.

Barrett-Connor E, Khaw KT. Diabetes mellitus: an independent risk factor for stroke? Am J Epidemiol 1988; 128:116–23. 10.1093/oxfordjournals.aje.a114934

Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005;365(9467):1333–46.

Frd, E. S., Giles, W. H. & Dietz, W. H. Prevalence the metabоlic syndrоme amng US adults: findings frm the third Natinal Health and Nutritin Examinatin Survey. JAMA 287, 356–359 (2002).

Teixeira TF, Alves RD, Moreira AP, Peluzio Mdo C. Main characteristics of metabolically obese normal weight and metabolically healthy obese phenotypes. Nutr Rev. 2015; 73:175–190.

Zinman B, Wanner C, Lachin JM, et al; EMPAREG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373:2117–2128.

Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016; 165:305–315.

Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of diabetes. Diabetologia. 2005;48(9):1684–99.

Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112(17):2735–52.

Lu Y, Hajifathalian K, Ezzati M, et al. Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1·8 million participants. Lancet 2014; 383:970–83. 10.1016/S0140-6736(13)61836-X.